A phase 3, double-blind, randomized placebo-controlled study was conducted in 551 patients with active rheumatoid arthritis who received secukinumab, abatacept, or placebo.
Findings come from 2 trials; one compared secukinumab with placebo, whereas the other compared secukinumab with placebo and etanercept.
Post-hoc analysis of the FUTURE-2 trial was performed to assess if there was a differential treatment responses to secukinumab in TNFi-exposed or naïve patients with active psoriatic arthritis.
Results from the FUTURE trials demonstrate significant reduction in disease burden and severity of PsA with secukinumab.
